NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis $11.70 +0.53 (+4.74%) Closing price 04:00 PM EasternExtended Trading$11.70 +0.01 (+0.04%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GH Research Stock (NASDAQ:GHRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GH Research alerts:Sign Up Key Stats Today's Range$11.20▼$11.8850-Day Range$8.66▼$12.8852-Week Range$6.00▼$20.50Volume135,998 shsAverage Volume180,926 shsMarket Capitalization$608.73 millionP/E RatioN/ADividend YieldN/APrice Target$30.43Consensus RatingBuy Company OverviewGH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Read More… GH Research Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreGHRS MarketRank™: GH Research scored higher than 49% of companies evaluated by MarketBeat, and ranked 535th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingGH Research has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGH Research has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GH Research's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($0.80) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -14.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -14.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.97% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently decreased by 2.08%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.97% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently decreased by 2.08%, indicating that investor sentiment is improving. News and Social Media1.6 / 5News Sentiment0.83 News SentimentGH Research has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for GH Research this week, compared to 3 articles on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GH Research's insider trading history. Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Email Address GHRS Stock News HeadlinesGH Research to Present at ASCP Meeting on Breakthrough Depression TreatmentMay 27 at 7:40 AM | tipranks.comGH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Buy" by BrokeragesMay 21, 2025 | americanbankingnews.comTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…May 27, 2025 | Crypto 101 Media (Ad)GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual MeetingMay 15, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), GH Research (GHRS) and NewAmsterdam Pharma Company (NAMS)May 11, 2025 | theglobeandmail.comPsychedelic: Compass, GH Research, MindMed report quarterly earningsMay 9, 2025 | finance.yahoo.comGH Research PLC: GH Research Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 8, 2025 | finanznachrichten.deGH Research Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 8, 2025 | globenewswire.comSee More Headlines GHRS Stock Analysis - Frequently Asked Questions How have GHRS shares performed this year? GH Research's stock was trading at $7.00 at the beginning of the year. Since then, GHRS shares have increased by 66.0% and is now trading at $11.62. View the best growth stocks for 2025 here. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) released its earnings results on Thursday, May, 8th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.42. When did GH Research IPO? GH Research (GHRS) raised $150 million in an IPO on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. Who are GH Research's major shareholders? Top institutional shareholders of GH Research include BVF Inc. IL (16.97%), RA Capital Management L.P. (13.35%), Cormorant Asset Management LP (3.86%) and Jefferies Financial Group Inc. (1.44%). How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GH Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that GH Research investors own include Baidu (BIDU), Shopify (SHOP), Bristol-Myers Squibb (BMY), Zoom Video Communications (ZM), Atai Life Sciences (ATAI), CRISPR Therapeutics (CRSP) and Caesars Entertainment (CZR). Company Calendar Last Earnings5/08/2025Today5/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GHRS CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$30.43 High Stock Price Target$40.00 Low Stock Price Target$14.00 Potential Upside/Downside+160.1%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.29% Return on Assets-19.49% Debt Debt-to-Equity RatioN/A Current Ratio15.83 Quick Ratio15.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares52,028,000Free Float30,384,000Market Cap$608.73 million OptionableOptionable Beta0.86 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:GHRS) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.